Developing a PAD Treatment Plan Including GDMT and Emerging Therapeutics: Undertreatment of PAD
Back to course
Video Transcription
0:00
Hi, my name is Philip Goodney. It's my pleasure today to talk about the undertreatment of peripheral arterial disease as part of
0:14
the symposium on the plan to develop a PAD treatment plan, including goal-directed medical therapy as well as emerging therapeutics. Thank you. These are my disclosures.
0:26
I want to make sure that we express our appreciation to both the American Heart Association and the Food and Drug Administration who provided funding support for some of
0:34
the work that we will share today.
0:37
I have three goals for the next 20 minutes or so. First, I'd like to summarize some recommendations for annual integrated preventive measures for
0:47
patients with peripheral arterial disease aimed at limiting the progression of their disease and improving their outcomes. Second, I'd like to outline
0:56
the adherence to these measures as well as treatments for severe peripheral arterial disease. Then third, I'd like to talk about ways to
1:05
potentially find some pathways forward to improve the care, even given the limitations in the dissemination of these preventive measures for
1:14
patients with peripheral arterial disease. I'd like to express my appreciation to the American College of Cardiology for asking us to be part of this work.
1:22
First, let's talk about the recommendations for annual integrated preventive measures for patients with peripheral arterial disease. As it's well-known, and this is work that we
1:33
published in the early 2012, that there is significant variation in care for patients with peripheral arterial disease. This is a map of Medicare patients
1:44
across the United States formed from a cohort of patients with both diabetes and peripheral arterial disease between 2007 and 2011. The colors in the map correspond to
1:57
amputation rates for those patients with severe peripheral arterial disease and diabetes. The darker colors, such as the red and brown, correspond to rates of amputation from
Video Summary
In this video, Philip Goodney discusses the undertreatment of peripheral arterial disease (PAD) and the need for annual integrated preventive measures to limit the progression of the disease and improve patient outcomes. He highlights the significant variation in care for patients with PAD, as shown by the variation in amputation rates across different regions of the United States. Goodney emphasizes the importance of certain preventive measures, including hemoglobin A1C testing, diabetic foot care, and vascular assessment. However, he notes that the provision of these measures is limited and adherence is low, particularly among high-risk populations such as African American, Hispanic, and Native American patients. Goodney also discusses the need for patient-level and population-level pathways to improve the delivery of preventive measures. He concludes by emphasizing the importance of focusing these efforts on the most at-risk populations.
Keywords
peripheral arterial disease
undertreatment
amputation rates
preventive measures
high-risk populations
delivery of preventive measures
Android App Download IOS App Download Powered By